HC Wainwright reissued their buy rating on shares of Can Fite Biopharma Ltd (NYSEMKT:CANF) in a research note published on Tuesday morning.

Separately, ValuEngine downgraded Can Fite Biopharma from a sell rating to a strong sell rating in a research report on Thursday, September 7th.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.watchlistnews.com/can-fite-biopharmas-canf-buy-rating-reiterated-at-hc-wainwright/1674836.html.

About Can Fite Biopharma

Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.

Receive News & Ratings for Can Fite Biopharma Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can Fite Biopharma Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.